Design of a phase 3, randomized, placebo-controlled trial of tofersen initiated in clinically presymptomatic SOD1 mutation carriers: The ATLAS Study

Benatar M (presenter), Wuu J, Andersen PM, Andrews J, Bucelli RC, Otto M, Ferguson TA, Chen W, Fanning L, Graham D, Sun P, Liu Y, Wong J, Fradette S. Design of a phase 3, randomized, placebo-controlled trial of tofersen initiated in clinically presymptomatic SOD1 mutation carriers: The ATLAS Study Oral presentation at the American Academy of Neurology Virtual Annual Meeting, Apr 17-22, 2021. [PubMed Link]